(NASDAQ: TNGX) Tango Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.11%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.32%.
Tango Therapeutics's earnings in 2026 is -$107,232,000.On average, 14 Wall Street analysts forecast TNGX's earnings for 2026 to be -$195,867,832, with the lowest TNGX earnings forecast at -$228,225,586, and the highest TNGX earnings forecast at -$180,737,654. On average, 13 Wall Street analysts forecast TNGX's earnings for 2027 to be -$225,202,443, with the lowest TNGX earnings forecast at -$265,081,892, and the highest TNGX earnings forecast at -$174,662,438.
In 2028, TNGX is forecast to generate -$244,368,301 in earnings, with the lowest earnings forecast at -$304,773,298 and the highest earnings forecast at -$164,030,812.